Abstract 13: Trends in treatment of uterine serous cancer in the medicare population

Autor: Rauh-Hain, JA, Connor, S., Clemmer, J.B., Clark, R.M., Hall, T., Growdon, W.B., Goodman, A.K., Boruta, D., II, Schorge, J.O., del Carmen, M.G.

Publikováno v: In Gynecologic Oncology June 2015 137(3):595-596

Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer.

Autor: Rauh-Hain, JA, del Carmen, M, Horowitz, NS, Alarcon, IA, Ko, E, Goodman, AK, Olawaiye, AB

Publikováno v: BJOG: An International Journal of Obstetrics & Gynaecology; Jan2010, Vol. 117 Issue 1, p32-38, 7p, 2 Charts, 4 Graphs

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

Autor: Sehouli J; Gynecology with Center for Oncological Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany jalid.sehouli@charite.de.; North-Eastern German Society of Gynaecological Oncology (NOGGO eV), Berlin, Germany., Boer J; North-Eastern German Society of Gynaecological Oncology (NOGGO eV), Berlin, Germany., Brand AH; Westmead Hospital, Westmead, New South Wales, Australia.; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Oza AM; Medical Oncology & Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., O'Donnell J; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Bennett K; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Glaspool R; Beatson West of Scotland Cancer Centre, Glasgow, UK., Lee CK; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia., Ethier JL; Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Harter P; Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.; AGO Study Group, Wiesbaden, Germany., Seebacher-Shariat V; AGO Austria, Innsbruck, Austria.; Medical University of Vienna, Vienna, Austria., Chang TC; Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.; Chang Gung University, Taoyuan, Taiwan., Cohen PA; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, Australia., van Gorp T; Gynaecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium., Chavez-Blanco A; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Welch S; Department of Oncology, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada., Hranovska H; National Academy of Medical Sciences of Ukraine, Kiiv, Ukraine., O'Toole S; Cancer Trials Ireland, Dublin, Ireland., Lok CAR; Department of Gynaecologic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands., Madariaga A; 12 de Octubre University Hospital, Madrid, Comunidad de Madrid, Spain.; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Rauh-Hain JA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Perez Fidalgo A; Medical Oncology, Hospital Clinico Universitario, Valencia, Spain., Tan D; National University Cancer Institute, Singapore., Michels J; Gustave Roussy, Villejuif, Île-de-France, France.; Université Paris-Saclay, Villejuif, Île-de-France, France., Pothuri B; NYU Langone Health Perlmutter Cancer Center, New York, New York, USA., Fujiwara N; Department of Palliative Medicine and Advanced Clinical Oncology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Minato-city, Tokyo, Japan.; Gynecologic Oncology Trial and Investigation Consortium (GOTIC), Moroyama, Japan., Rosengarten O; Medical Gyneco-Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel., Nishio H; Department of Obstetrics and Gynecology, Keio Univesity School of Medicine, Tokyo, Japan.; Japanese Gynecologic Oncology Group (JGOG), Tokyo, Japan., Kim SI; Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea (the Republic of)., Mukopadhyay A; Kolkata Gynecological Oncology Trials and Translational Research Group (KolGOTrg), Kolkata, India., Piovano E; Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy., Cecere SC; Dep. of Experimental Uro-Gynecological Oncology, National Cancer Institute Institute for Hospitalization and Care Scientific Foundation Pascale, Naples, Italy., Kohn EC; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA., Mukherjee U; GynaeOncology Trials Group UK (GCG UK), London, UK., Nasser S; Department of Gynecology with Center of Oncological Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany.; Pan-Arabian Research Society of Gynecological Oncology, Berlin, Germany., Lindemann K; Department of gynecological oncology, Oslo University Hospital, Oslo, Norway.; Nordic Society of Gynaecological Oncology (NSGO), Copenhagen, Denmark., Croke J; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Chen X; Tongji University Dongfang Hospital, Shanghai, Shanghai, China., Geissler F; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland.; Swiss GO Trial Group, Basel, Switzerland., Bookman MA; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada.; Kaiser Permanente Northern California, Oakland, California, USA.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Nov 04; Vol. 34 (11), pp. 1677-1684. Date of Electronic Publication: 2024 Nov 04.

The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.

Autor: Barakzai SK; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Bregar AJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Del Carmen MG; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Eisenhauer EL; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Goodman A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Rauh-Hain JA; Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX, United States of America., Gockley AA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America., Melamed A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States of America. Electronic address: alexander.melamed@mgh.harvard.edu.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Nov; Vol. 190, pp. 119-123. Date of Electronic Publication: 2024 Aug 22.

The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy.

Autor: Nitecki Wilke R; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA rnitecki@mdanderson.org., Liu J; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Teaxs, USA., Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fellman BM; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sims TT; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pham M; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rangel K; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sey E; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rauh-Hain JA; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lu KH; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fleming ND; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.